There is increasing evidence for the existence of multiple levels of crosstalk between ERα and HER2 signaling pathways in breast cancers, which lead to tumor progression and therapy resistance (Osborne and Schiff, 2011; Montemurro et al., 2013). The gene discussed is ERBB2; the disease is neoplasm.